IMCD N.V. has announced that it has successfully raised approximately EUR 400 million through an accelerated bookbuild offering of 4,395,604 newly issued ordinary shares at an offer price of EUR 91.00 per ordinary share. The net proceeds of the offering will be used by the company for general corporate purposes and to finance the acquisition of 70% of Signet Excipients Private Limited, one of the leading distributors of excipients in India.

 

The newly issued shares represent 8.4% of IMCD’s issued share capital before the capital increase and 7.7% after the transaction. 

 

Allocation of the new shares has taken place today, 16 September 2020. Payment and delivery of the newly issued shares are scheduled for 18 September 2020, at which date the new shares are expected to be admitted to listing and trading on Euronext Amsterdam. After settlement the total number of issued ordinary shares of IMCD will amount to 56,987,858. The new shares will rank pari passu in all respects with the outstanding ordinary shares of the company, including any rights to dividends.

 

In relation to the offering, the company is subject to a market customary lock-up ending 90 days after the issue date, subject to customary exceptions and waivable by the sole global coordinator.

J.P. Morgan Securities plc acted as sole global coordinator and, together with BNP PARIBAS and HSBC Bank plc, as joint bookrunners in connection with the offering.